Is Coherus Oncology, Inc. (CHRS) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 99.2% / 30% | 46.3% / 30% | 45.0% / 30% | 62.68% / 5% | ✗ NOT HALAL |
| DJIM | 99.2% / 33% | 46.3% / 33% | 45.0% / 33% | 62.68% / 5% | ✗ NOT HALAL |
| MSCI | 60.2% / 33% | 28.1% / 33% | 27.3% / 33% | 62.68% / 5% | ✗ NOT HALAL |
| S&P | 99.2% / 33% | 46.3% / 33% | 45.0% / 33% | 62.68% / 5% | ✗ NOT HALAL |
| FTSE | 60.2% / 33% | 28.1% / 33% | 27.3% / 50% | 62.68% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 67.2% | |
| Operating Margin | -339.5% | |
| Net Margin | 398.4% | |
| Return on Assets (ROA) | -31.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$139M |
| Free Cash Flow | -$139M |
| Total Debt | $40M |
| Debt-to-Equity | 89.1 |
| Current Ratio | 1.5 |
| Total Assets | $258M |
Price & Trading
| Last Close | $1.66 |
| 50-Day MA | $1.83 |
| 200-Day MA | $1.40 |
| Avg Volume | 2.2M |
| Beta | 1.1 |
|
52-Week Range
$0.71
| |
About Coherus Oncology, Inc. (CHRS)
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Coherus Oncology, Inc. (CHRS) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Coherus Oncology, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Coherus Oncology, Inc.'s debt ratio?
Coherus Oncology, Inc.'s debt ratio is 99.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 60.2%.
What are Coherus Oncology, Inc.'s key financial metrics?
Coherus Oncology, Inc. has a market capitalization of $244M, and revenue of $42M. The company maintains a gross margin of 67.2% and a net margin of 398.4%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.